<?xml version="1.0" encoding="UTF-8"?>

<?xml-stylesheet type="text/xsl" href="/static/oaitohtml.xsl"?>

<!--
<?xml-stylesheet type="text/xsl" href="/oaitohtml.xsl"?>
-->

<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <responseDate>2026-10-11T22:55:06Z</responseDate>
    <request verb="GetRecord" metadataPrefix="oai_dc" identifier="10.57760/sciencedb.35019" >https://www.scidb.cn/oai</request>
<GetRecord>
    <record>
    <header >
    <identifier>10.57760/sciencedb.35019</identifier>
    <datestamp>2026-05-06T21:43:41Z</datestamp>
</header>
    <metadata>
        
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:date>2026-05-06</dc:date>
  <dc:title>Essential fatty acids disrupt the mycolic acid-rich cell envelope of clinical Nocardia isolates: A membrane-targeting approach to combat persistent infections</dc:title>
  <dc:identifier>doi:10.57760/sciencedb.35019</dc:identifier>
  <dc:language>en</dc:language>
  <dc:description>Conventional antibiotics against slow‑growing, mycolic acid‑rich Nocardia often require prolonged therapy and are associated with high relapse rates. We evaluated five essential fatty acids (EFAs) against 82 clinical Nocardia isolates. &amp;alpha;-Linolenic acid, &amp;gamma;-linolenic acid, eicosapentaenoic acid and docosahexaenoic acid (DHA) exhibited comparable activity (MIC50 / MIC90: 31.25/62.50 &amp;mu;M), corresponding to mass concentration ranges of 8.7 to 10.3 &amp;mu;g/mL for MIC50 and 17.4 to 20.6 &amp;mu;g/mL for MIC90. However, arachidonic acid was markedly less active. Using DHA as a representative EFA, we showed that it rapidly disrupts the mycolic acid‑rich cell envelope, causing propidium iodide influx and ultrastructural damage, and achieves concentration‑dependent bactericidal killing within 1 h, a feat not observed with imipenem. Transcriptomic analysis revealed that surviving cells enter a state of metabolic sensitization, characterized by a maladaptive transcriptional response involving the downregulation of the proton-pumping Nuo complex, compensatory upregulation of the type II NADH dehydrogenase (Ndh), and a global induction of protein synthesis machinery. Critically, this DHA-induced disruption of the permeability barrier and metabolic reprogramming restored the efficacy of aminoglycosides; subinhibitory concentrations of DHA significantly potentiated amikacin activity against intrinsically resistant N. wallacei isolates (FICI: 0.51&amp;ndash;0.56). These findings establish DHA as a dual-action agent that both kills Nocardia via membrane disruption and sensitizes persistent cells to co-administered antibiotics, offering a rational membrane-targeting strategy to combat recalcitrant mycolic acid-rich pathogens.</dc:description>
  <dc:subject>essential fatty acids; Nocardia; mycolic acid; metabolic sensitization; aminoglycoside synergy</dc:subject>
  <dc:creator>Ming Wei</dc:creator>
  <dc:creator>Shiwang Xie</dc:creator>
  <dc:creator>Peng Wang</dc:creator>
  <dc:creator>Tianmeng Li</dc:creator>
  <dc:creator>Jun Liu</dc:creator>
  <dc:creator>Jingxian Yang</dc:creator>
  <dc:creator>Xinmin Xu</dc:creator>
  <dc:creator>Dan Luo</dc:creator>
  <dc:creator>Li Gu</dc:creator>
  <dc:creator>Shuai Wang</dc:creator>
  <dc:rights>PUBLIC</dc:rights>
  <dc:rights>https://creativecommons.org/licenses/by/4.0/</dc:rights>
  <dc:type>dataset</dc:type>
  <dc:publisher>Science Data Bank</dc:publisher>
</oai_dc:dc>

    </metadata>
</record>
</GetRecord>
</OAI-PMH>